Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN10018 and Dalpiciclib in Progressive Meningiomas
NCT07652762Phase 1Recruiting
- Sponsor
- Capital Medical University
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ifebemtinib in meningioma, sponsored by Capital Medical University. Primary endpoints: Incidence of Dose-Limiting Toxicities at 4 weeks and Incidence of Treatment-Emergent Adverse Events at 24 months. Started Aug 2026; status: recruiting.
02
Drugs
ifebemtinib
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT07652762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652762.